Different safety profiles of risperidone and paliperidone extended-release: A double-blind, placebo-controlled trial with healthy volunteers

Human Psychopharmacology

Volumn 27, Issue 3, 2012, Pages 305-314

  Yoon, Kil Sang ^a   Park, Tae Won ^a   Yang, Jong Chul ^a   Kim, Min Gul ^a   Oh, Keun Young ^a   Park, Myung Sook ^b   Chung, Young Chul ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Chonbuk National University   (South Korea)

Author keywords

cognitive function; negative symptoms; paliperidone; schizophrenia

Indexed keywords

PALIPERIDONE; PLACEBO; RISPERIDONE;

ABDOMINAL DISCOMFORT; ADULT; AGITATION; AKATHISIA; ARTICLE; ASSESSMENT OF NEGATIVE SYMPTOMS SCALE; BLURRED VISION; COGNITION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERTHERMIA; HYPERVENTILATION; HYPOSALIVATION; MALE; MOOD DISORDER; NEGATIVE SYNDROME; NEUROLEPTIC INDUCED DEFICIT SYNDROME SCALE; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEDATION; SIDE EFFECT; STROOP TEST;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; COGNITION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; ISOXAZOLES; MALE; NEUROPSYCHOLOGICAL TESTS; PAIN MEASUREMENT; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; RISPERIDONE; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 84861175993     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2227     Document Type: Article

References (29)

1. Andreasen NC,. 1989. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 7: 49-58.
2. 2 receptor occupancy in patients with schizophrenia. Psychopharmacology 197: 229-235.
3. Artaloytia JF, Arango C, Lahti A, et al,. 2006. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 163: 488-493. (Pubitemid 44469392)
4. Awad AG,. 1993. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 19: 609-618. (Pubitemid 23272627)
5. Barrett SL, Bell R, Watson D, King DJ,. 2004. Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers. J Psychopharmacol 18: 156-172. (Pubitemid 38954902)
6. Basso MR, Bornstein RA, Lang JM,. 1999. Practice effects on commonly used measures of executive function across twelve months. Clin Neuropsychol 13: 283-292. (Pubitemid 30040140)
7. Bond A, Lader M,. 1974. The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211-218
8. Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM,. 2008. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 23: 209-215.
9. Canuso CM, Grinspan A, Kalali A, et al,. 2010. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol 25: 115-164.
10. Chouinard G, Margolese HC,. 2005. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 76: 247-265. (Pubitemid 40804771)
11. Dikmen SS, Heaton RK, Grant I, Temkin NR,. 1999. Test-retest reliability and practice effects of expanded Halstead-Reitan neuropsychological test battery. J Int Neuropsychol Soc 5: 346-356. (Pubitemid 29292201)
12. First MB, Gibbon M, Spitzer RL, Williams JB,. 1996. Structured Clinical Interview for Axis I DSM-IV Disorders-patient edition (SCID-I/P, Version 2.0, February 1996 Final Version). Biometrics Research Department, New York State Psychiatric Institute.
13. Han OS, Hong JP,. 2000. Structured Interview for Axis I DSM-IV. Hana publishing company: Seoul.
14. Inada T, Beasley CM, Jr, Tanaka Y, Walker DJ,. 2003. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol 18: 39-48. (Pubitemid 36127060)
15. Janicak PG, Winns EA,. 2007. Paliperidone ER: a review of the clinical trial data. Neuropsychiatr Dis Treat 3: 869-883.
16. Kay SR, Fiszbein A, Opler LA,. 1987. The Positive and Negative Symptoms Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276. (Pubitemid 18039085)
17. Marino J, Caballero J,. 2008. Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 28: 1283-1298.
18. Mizrahi R, Rusjan P, Agid O, et al,. 2007. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry 164: 630-637. (Pubitemid 46650195)
19. Naber D, Moritz S, Lambert M, et al,. 2001. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 50: 79-88. (Pubitemid 32510889)
20. Owen RT,. 2007. Extended-release paliperidone:efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today (Barc) 43: 249-258. (Pubitemid 47164420)
21. Pani L, Marchese G,. 2009. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opin Drug Deliv 6: 319-331.
22. Park CH, Park TW, Yang JC, et al,. 2012. No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial. Int Clin Psychopharmacol 27: 114-120.
23. Reilly JL, Harris MSH, Keshavan MS, Sweeney JA,. 2006. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry 63: 1189-1197. (Pubitemid 44708076)
24. Reilly JL, Harris MSH, Khine TT, Keshavan MS, Sweeney JA,. 2007. Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia. Biol Psychiatry 62: 818-821. (Pubitemid 47374643)
25. Schotte A, Bonaventure P, Janssen PF, Leysen JE,. 1995. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 69: 399-412. (Pubitemid 26013775)
26. Schotte A, Janssen PF, Gommeren W, et al,. 1996. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124: 57-73. (Pubitemid 26112775)
27. Seeman P,. 2005. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 162: 1984-1985. (Pubitemid 41428639)
28. Taira M, Hashimoto T, Takamatsu T, Maeda K,. 2006. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects. Prog Neuropsychopharmacol Biol Psychiatry 30: 1139-1142. (Pubitemid 43949431)
29. Van Putten T, May PRA,. 1978. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry 35: 477-480. (Pubitemid 8337039)